Sign up
Pharma Capital

Launch of synthetic bone graft opens up 'exciting' new market and opportunities for WideCells

WideCells Group PLC (LON:WIDE) Chief executive Joao Andrade and Chief Scientific Officer Peter Hollands chat through the launch of a new synthetic bone graft in the UK that will be used initially in tooth fillings.

Andrade also discusses the recent launch of the Cellplan e-commerce platform in the UK.

 

View full WDC profile

WideCells Group Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.